NCT03213977View on ClinicalTrials.gov

R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

July 13, 2023

Study Completion Date

July 13, 2024

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

R-DA-EPOCH

R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.

DRUG

R-CEOP90

R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.

Trial Locations (1)

350001

Fujian Medical University Union Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT03213977 - R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL | Biotech Hunter | Biotech Hunter